Asset Recommendation

At Evaluate, our mission is simple: to help patients gain access to life-saving therapies. Evaluate is a Norstella company, a collection of prominent pharmaceutical solutions providers that have joined forces to offer a full range of consultancy services and solutions. Evaluate provides life sciences clients with the right tools and expertise to navigate complexities at each step of the drug development life cycle, from pipeline to patient. Our offerings include cutting-edge data solutions, consensus forecasts and expert advisory services alongside advanced technologies such as machine learning and predictive analytics.

Asset Recommendation is a comprehensive listing that enables the evaluation of a drug’s potential value and market performance. This listing has been designed using data from Evaluate and Citeline to support decision making on drug development, investment opportunities and insight into deals providing insight into previous licensing agreements.

Asset recommendation involves evaluating various factors to determine which assets have the highest potential for success, both in terms of scientific viability and commercial potential. This assessment is based on a combination of scientific data, market research, regulatory considerations, and financial projections.

The following sets of data have been included in this listing.

Names and Identifiers: This data can be used to track specific drugs across different databases and sources.

Classifications: Drug classifications can provide insights into the types of drugs that are popular or successful in the market.

Product Sales: Sales data is crucial for assessing a drug’s market performance.

Patents: Information about patents can help assess a drug’s potential profitability.

Sales by Indication: This data can provide insights into the demand for treatments for specific conditions or diseases.

Deals - Licensing, product sales, platforms: This data provides information about past deals, which can inform future deal-making strategies.

NPV (Net Present Value): NPV data can help assess the potential profitability of a drug or indication.

Events: Information about events related to a drug can provide context for its performance and potential challenges.

Predicted Approvals: Predictions about future drug approvals can inform investment and development decisions.

Trial Costs: Data about clinical trial costs can help assess the feasibility and potential success of a drug.

Peak Sales: Information about a drug’s peak sales can provide insights into its market success.

Drugs@FDA: Data from the FDA can provide authoritative information about a drug’s approval status and attributes.

Indication-level Treatment Information: This data provides detailed information about treatments for specific indications, which can inform development and marketing strategies for drugs targeting those indications.

Consumers can use this data to analyze trends, make predictions, and inform your decision-making process in the pharmaceutical industry.

Once you subscribe to this listing, you will have access to all the data tables required.

Workflow:

• Consumer clicks Request button on Evaluate listing<br/>• Evaluate will reach out to the consumer and finalize terms.<br/>• Evaluate shares the data product with the consumer via Snowflake shares.

Additional Information<br/>This data product is updated regularly to ensure that you have the most recent and accurate information. If you have any questions or need further information, please don’t hesitate to contact us.